<DOC>
	<DOCNO>NCT01487239</DOCNO>
	<brief_summary>This study open-label , non-randomized , absorption , metabolism , excretion study [ 14C ] -GDC-0980 administer 10-mg oral dose 6 healthy postmenopausal and/or surgically sterile female subject follow least 10-hour fast food ( include water ) .</brief_summary>
	<brief_title>Study Investigate Absorption , Metabolism , Excretion 14C-GDC-0980 Following Single Oral Dose Administration Healthy Postmenopausal Female Subjects</brief_title>
	<detailed_description />
	<criteria>Medically healthy determine absence clinically significant finding medical history , physical examination , vital sign , 12lead ECG , clinical laboratory evaluation within reference range test laboratory , unless deem clinically significant Investigator Female subject nonchildbearing potential , define either : postmenopausal without recent history menorrhea document either physician note confirm serum folliclestimulating hormone level consistent postmenopausal status , surgically sterile BMI range within 18.5 29.9 kg/m2 , inclusive Negative test select drug abuse Screening Checkin Negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] , hepatitis C virus antibody [ antiHCV ] negative HIV antibody screen Minimum 1 2 bowel movement per day Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug History presence inflammatory disease , include small large intestine inflammation Crohn 's disease ulcerative colitis , require immunosuppressant Use potent protonpump inhibitor omeprazole , lansoprazole , dexlansoprazole , esomeprazole , pantoprazole , rabeprazole History Gilbert 's Syndrome History diabetes mellitus and/or elevate fast glucose baseline History presence abnormal ECG History alcoholism drug addiction within 1 year prior Checkin Participation one radiolabeled investigational study drug trial within 12 month prior Checkin . The previous radiolabeled study drug must receive 6 month prior Checkin study total exposure study previous study within recommend level consider safe Exposure significant radiation 12 month prior Checkin Use tobaccocontaining nicotinecontaining product within 3 months/approximately 90 day prior Checkin positive urine screen cotinine Participation investigational study drug trial receipt investigational study drug occur within 5 halflives 30 day , whichever longer , prior Checkin Use prescription medications/products within 14 day prior Checkin , unless deem acceptable Investigator Use overthecounter ( OTC ) , nonprescription preparation within 7 day prior Checkin Use alcohol , grapefruit , caffeinecontaining food beverage within 72 hour Poor peripheral venous access Donation blood 30 day prior Screening plasma 2 week prior Screening Receipt blood product within 2 month prior Checkin Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>